Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT06245018 Not yet recruiting - Solid Tumor Clinical Trials

A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.

NCT ID: NCT06241898 Recruiting - Solid Tumor Clinical Trials

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Start date: October 1, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: - to assess the safety and tolerability of BB-1709. - to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709

NCT ID: NCT06239623 Recruiting - Melanoma Clinical Trials

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

JSI-1187-101 phase 1 study

NCT ID: NCT06239298 Not yet recruiting - Solid Tumor Clinical Trials

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.

NCT ID: NCT06237413 Recruiting - Solid Tumor Clinical Trials

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Start date: August 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.

NCT ID: NCT06234423 Recruiting - Ovarian Cancer Clinical Trials

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Start date: February 9, 2024
Phase: Phase 1
Study type: Interventional

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

NCT ID: NCT06234098 Recruiting - Solid Tumor Clinical Trials

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Start date: February 13, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.

NCT ID: NCT06220318 Recruiting - Solid Tumor Clinical Trials

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Start date: July 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

NCT ID: NCT06215846 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

NCT ID: NCT06212076 Not yet recruiting - Solid Tumor Clinical Trials

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Start date: February 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).